Loading...
Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)
Menis, J. Bironzo, P. Radj, G. Greillier, L. Monnet, I. Livi, L. Young, R. Decroisette, C. Cloarec, N. Robinet, G.
Menis, J.
Bironzo, P.
Radj, G.
Greillier, L.
Monnet, I.
Livi, L.
Young, R.
Decroisette, C.
Cloarec, N.
Robinet, G.
Citations
Altmetric:
Abstract
Background: SCLC is characterized by large number of CTCs that have demonstrated
prognostic value. We evaluated CTC count and PD-L1 expression on CTCs in the REACTION
trial, a multicenter, open-label, randomized phase II trial.
Methods: In the REACTION trial, patients with ED-SCLC, unselected for PD-L1, with PS
0/1 and controlled brain metastases who achieved an objective response after 2 X Pl-
E were randomized 1:1 to experimental arm (EXP) P in combination with 4 X Pl-E then
P up to a total of 35 cycles vs. 4 X Pl-E in the control (CTRL) arm. Cross-over to P-Pl-E
was allowed for CTRL. Primary endpoint was progression free survival (PFS) from
randomization. CTCs were collected with Streck tubes after registration and during
the first 2 cycles of induction chemotherapy (at the discretion of the investigator),
before randomization and every 2 cycles during treatment and at end of treatment.
Results: Between Feb 7, 2018 and Oct 31, 2019, 125 patients were recruited (61 in
EXP arm vs 64 in CTRL arm) with 119 (58 vs 61) eligible and receiving at least one dose
of treatment (Per Protocol [PP] population). Median age was 65 vs 63.5 years with the
majority being male (72 vs 56%), PS 1 (62 vs 60%), and rare brain metastases (8 vs
11%). Most patients had partial response (PR) to the induction chemo (98% in each
arm). 19 patients crossed over to P-E-Pl. Among 124 patients who started treatment,
grade 3 adverse events were observed in 43 vs 36%, while only 2 patients (1 in each
arm) had grade 5 toxicity. Among PP patients, 107 PD or deaths were observed. The
response rate was 61% (67 vs 56%). Median follow-up time with respect to OS was
14.2 months in EXP and 14.0 months in CTRL arm. Median PFS (80% CI) was 4.7
months (4.5, 5.3) vs 5.4 (4.9, 5.5), HR ¼ 0.84 (0.65, 1.09) and 1-sided p¼0.194.
Median OS (80% CI) was 12.3 months (10.2, 14.5) vs 10.4 (8.5, 11.6), HR ¼ 0.73 (0.54,
1.0) and 1-sided p¼0.097.
Conclusions: P combined with Pl-E was well tolerated, did not improve PFS but OS
was significantly improved. CTC analysis are in finalization and results will be presented
during the congress.
Description
Date
2020
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Menis J, Bironzo P, Radj G, Greillier L, Monnet I, Livi L, et al. 9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994). Annals of Oncology. 2020;31:S1420-S.